Meeting
2022 ASCO Genitourinary Cancers Symposium
A microRNA-based classifier for identification of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
Authors
Sharanjot Saini
Augusta University, Augusta, GA
Sharanjot Saini , Divya Bhagirath , Nikhil Patel , Ashok Sharma , Tae Jin Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 149)
DOI
10.1200/JCO.2022.40.6_suppl.149
Abstract #
149
Poster Bd #
H8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Adherence to oral treatments in elderly patients with advanced prostate cancer: The ADHERE study, a prospective trial of the Meet-URO network.
First Author: Pasquale Rescigno
Poster
2021 ASCO Annual Meeting
A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).
First Author: Tim Warneke
Poster
2020 Genitourinary Cancers Symposium
Non-rising PSA disease progression on C-11 choline PET/CT imaging in patients receiving second generation hormone therapies (2nd-HT).
First Author: Mohamed E. Ahmed
Poster
2018 Genitourinary Cancers Symposium
Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate (AA) and enzalutamide (E) in advanced prostate cancer: clinical value and cost considerations.
First Author: Sarah Wong